Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.0056 | 0.167 | 0.167 |
Loa Loa (eye worm) | D-ets-4 DNA binding domain-containing protein | 0.0081 | 0.2776 | 0.2776 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.0056 | 0.167 | 0.167 |
Schistosoma mansoni | gabp alpha | 0.0081 | 0.2776 | 0.2776 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0133 | 0.5077 | 0.5077 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.0056 | 0.167 | 0.167 |
Echinococcus multilocularis | GA binding protein alpha chain | 0.0081 | 0.2776 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0069 | 0.2261 | 0.2261 |
Echinococcus granulosus | GA binding protein alpha chain | 0.0081 | 0.2776 | 1 |
Brugia malayi | Ets-domain containing protein | 0.0081 | 0.2776 | 0.2776 |
Schistosoma mansoni | hypothetical protein | 0.0038 | 0.0897 | 0.0897 |
Loa Loa (eye worm) | hypothetical protein | 0.0056 | 0.167 | 0.167 |
Loa Loa (eye worm) | hypothetical protein | 0.0038 | 0.0897 | 0.0897 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0038 | 0.0897 | 0.0897 |
Brugia malayi | MH2 domain containing protein | 0.0133 | 0.5077 | 0.5077 |
Brugia malayi | Ets-domain containing protein | 0.0081 | 0.2776 | 0.2776 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0133 | 0.5077 | 0.5077 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | > 60 uM | Inhibition of recombinant human MAOA using p-tyramine as substrate assessed as H2O2 production preincubated for 15 mins followed by substrate addition by fluorometric analysis | ChEMBL. | 26352677 |
IC50 (binding) | > 60 uM | Inhibition of recombinant human MAOB using p-tyramine as substrate assessed as H2O2 production preincubated for 15 mins followed by substrate addition by fluorometric analysis | ChEMBL. | 26352677 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.